The global vascular stents market is expected to reach $8.8bn by 2021, driven primarily by the growing prevalence of cardiovascular disease, the leading cause of death worldwide. Limitations of current stent products are fueling innovations by the three big heart players - Abbott, Boston Scientific and Medtronic - as well as startups to develop next-generation drug-eluting and bioresorbable stents that can reduce the risk of adverse event. This feature looks more closely at the competitive landscape of the overall vascular stent market focusing in particular on the changing dynamics of drug-eluting stents, which is the largest and second-fastest segment in this overall market, including its use for treating peripheral artery disease, along with physician surveys and perspectives.
The global market for vascular stents, used for unblocking arteries or relieving obstruction of blood flow resulting from heart disease, is expected to rise from $6.5bn in 2016 to $8.8bn by 2021, representing a CAGR of 6.2%.
